趋势研判！2026年中国侵袭性真菌病诊断试剂行业政策、产业链、市场规模、竞争格局及发展趋势：行业展现出强劲的发展潜力，未来增长前景持续向好[图]

Core Viewpoint - The invasive fungal disease (IFD) diagnostic reagent market in China is expected to grow significantly, driven by increasing demand due to an aging population, rising incidence of high-risk groups, and improved health awareness, with market size projected to reach 12.4 billion yuan by 2026 from 2.4 billion yuan in 2018 [1][5]. Group 1: Industry Overview - Invasive fungal disease (IFD) is characterized by fungi invading human tissues and blood, leading to significant health complications, particularly in immunocompromised individuals [2][4]. - The demand for IFD diagnostics is increasing due to a growing base of immunocompromised individuals and the rising incidence of IFD in China [5][6]. Group 2: Market Size and Growth - The market for IFD diagnostic reagents in China is projected to grow from 2.4 billion yuan in 2018 to 7.9 billion yuan in 2024, surpassing 10 billion yuan in 2025, and reaching approximately 12.4 billion yuan by 2026 [1][5]. - The growth is supported by healthcare cost control measures, tiered medical services, and heightened health awareness among the population [5][6]. Group 3: Industry Chain - The IFD diagnostic reagent industry chain includes upstream biological raw materials, chemical additives, consumables, and related equipment; midstream involves the production of diagnostic reagents; and downstream applications are in medical institutions, third-party laboratories, and research institutions [2][6]. Group 4: Competitive Landscape - The market is concentrated, with over ten domestic and international companies holding product registrations, including major players like Danna (Tianjin) Biotechnology Co., Ltd., Tianjin Yirui Biotechnology Co., Ltd., and Zhanjiang Andus Biological Co., Ltd. [2][6][7]. - Danna Biotech has developed a comprehensive testing solution for IFD, with a significant presence in over 1,300 medical institutions across China [7]. Group 5: Industry Trends - The IFD diagnostic reagent sector is poised for growth due to healthcare reforms, cost control measures, and increasing health consciousness, with a strong demand for early diagnosis driven by the rising incidence of IFD [8]. - The industry is transitioning towards high-technology, high-quality, and high-throughput standards, narrowing the technological gap with developed countries [8].